This announcement is a separate document:
Mayne Pharma Group Ltd: Approval of additional KAPANOL dosages in Switzerland
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.